Tiagabine in the treatment of epilepsy - A clinical review with a guide for the prescribing physician

Epilepsy Research

Volumn 41, Issue 3, 2000, Pages 245-251

  Schmidt, D ^a   Gram, L ^b   Brodie, M ^c   Kramer G ^d   Perucca, E ^e   Kalviainen R ^f   Elger, C E ^g  

^a Epilepsy Research Group   (Germany)

^b HVIDOVRE HOSPITAL   (Denmark)

^c WESTERN INFIRMARY   (United Kingdom)

^d SWISS EPILEPSY CENTER   (Switzerland)

^e Univ P   (Italy)

^f KUOPIO UNIVERSITY HOSPITAL   (Finland)

^g UNIVERSITY OF BONN   (Germany)

Author keywords

Antiepileptic drug; Drug evaluation; Drug therapy; Patient profile; Prescribing guide; Tiagabine

Indexed keywords

TIAGABINE;

DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; EPILEPSY; GASTROINTESTINAL SYMPTOM; HUMAN; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

EID: 0034308127     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(00)00149-2     Document Type: Article

References (34)

1. Abou-Khalil B.W. Tiagabine-related stupor: evidence for a nonepileptic origin. Neurology. 54(Suppl. 3):2000;A194.
2. Adkins J.C., Noble S. Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs. 55:1998;437-460.
3. Ben-Menachem E. International experience with tiagabine add-on therapy. Epilepsia. 36(Suppl. 6):1995;S14-S21.
4. Borden L.A., Murali Dhar T.G., Smith K.E., Weinshank R.L., Branchek T.A., Gluchowski C. Tiagabine, SKF 89976-A, CI-966 and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur. J. Pharmacol. 269:1994;219-224.
5. Brodie M.J. Tiagabine pharmacology in profile. Epilepsia. 36(Suppl. 6):1995;S7-S9.
6. Cato A. III, Gustavson L.E., Qian J., El-Shourbagy T., Kelly E.A. Effects of renal impairment on the pharmacokinetics and tolerability of tiagabine. Epilepsia. 39:1998;43-47.
7. Collins S.D., Brun S., Kirstein Y.G., Sommerville K.M. Absence of visual field defects in patients taking tiagabine. Epilepsia. 39(Suppl. 6):1998;146-147.
8. Dean A.C., Gosey C., Matsuo F Utility of tiagabine in epilepsy patients with glial tumors. Epilepsia. 39(Suppl. 6):1998;57.
9. Dodrill C.B., Amett L.J., Sommerville K.W., Shu V. Cognitive and quality of life effects of differing doses of tiagabine in epilepsy. Neurology. 48:1997;1025-1031.
10. Gustavson L.E., Mengel H.B. Pharmacokinetics of tiagabine, a γ-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. Epilepsia. 36:1995;605-611.
11. Gustavson L.E., Boellner S.W., Grannemann G.R., Qian J.X., Guenther H.J., El-Shourbagy T., Sommerville K.W. A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. Neurology. 48:1997;1032-1037.
12. Kälviäinen R., Äikia M., Mervaala E., Saukonen A.M., Pitkänen A., Riekkinen P.J. Sr Long-term cognitive and EEG effects of tiagabine in drug-resistant partial epilepsy. Epilepsy Res. 25:1996;291-297.
13. Kälviäinen R., Brodie M.J., Duncan J., Chadwick D., Edwards D., Lyby K. A double-blind, placebo-controlled trial of tiagabine given three times daily as add-on therapy for refractory partial seizures. Epilepsy Res. 30:1998a;31-40.
14. Kälviäininen R., Salmenperä T., Leena J., Pedersen P.C., Perry D., Riekkinen P. Slow versus fast drug switch from established AED to tiagabine. Epilepsia. 39(2):1998b;66.
15. Kälviäinen, R., Nousianen, J., Mantyjärvi, M., Riekkinen, P., 1999. Absence of concentric visual field defects in patients with long-term tiagabine monotherapy. Neurology (Suppl. 2), A236.
16. Krämer G. Pharmacokinetic interactions of new antiepileptic drugs. Stefan H., Krämer G., Mamoli B. Challenge Epilepsy - New Antiepileptic Drugs. 1998;87-103 Blackwell Scientific Publications, Berlin.
17. Lau A.H., Gustavson L.E., Sparelakis R., Lam N.P., El-Shoubagy T., Qian J.Y., Layden T. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. Epilepsia. 38:1997;445-451.
18. Leach J.P., Brodie M.J. Tiagabine. Lancet. 351:1998;203-207.
19. Leppik I. Tiagabine: the safety landscape. Epilepsia. 36(Suppl. 6):1995;S10-S13.
20. Leppik I., Gram L., Deaton R., Sommerville K. Safety of tiagabine: summary of 53 trials. Epilepsy Res. 33:1999;235-246.
21. Loiseau P. Review of controlled trials of Gabitril (tiagabine): a clinician's viewpoint. Epilepsia. 40(suppl.):1999;S14-S19.
22. Mengel H. Tiagabine. Epilepsia. 35(Suppl. 5):1994;S81-S84.
23. Mengel H.B. Tiagabine: evaluation of the risk of interaction with theophylline, warfarin, digoxin, cimetidine, oral contraceptives, triazolarn or ethanol. Epilepsia. 36(Suppl. 3):1995;160.
24. Mengel H.B., Houston A., Back D.J. An evaluation of the interaction between tiagabine and oral contraceptives in female volunteers. J. Pharm. Med. 4:1994;141-150.
25. Richens A., Chadwick D.W., Duncan J.S., Dam M., Gram L., Mikkelsen M., Morrow J., Mengel H., Shu V., McKelvy J.F., Pierce M.W. Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial. Epilepsy Res. 21:1995;37-42.
26. Schachter S.J. Tiagabine monotherapy in the treatment of partial epilepsy. Epilepsia. 36(Suppl. 6):1995;S2-S6.
27. Schachter S.C. Tiagabine: current status and potential clinical applications. Expert Opin. Invest. Drugs. 5(109):1996;1377-1387.
28. Schachter S.C. Tiagabine. Epilepsia. 40(Suppl. 5):1999;S17-S22.
29. Schachter S.C., Cahill W.T., Wannamaker B.B., Shu V.S., Sommerville K.W. Open-label dosage and tolerability study of tiagabine monotherapy in patients with refractory complex partial seizures. J. Epilepsy. 11:1998;248-255.
30. Snel S., Jansen J.A., Mengel H.B., Richens A., Larsen S. The pharmacokinetics of tiagabine in healthy elderly volunteers and elderly patients with epilepsy. J. Clin. Pharmacol. 37:1997;1015-1020.
31. So E.L., Wolff D., Graves N., Leppik I., Cascino G.D., Pixton G.C., Gustavson L.E. Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. Epilepsy Res. 22:1995;221-226.
32. Suszdak P.D., Jansen J.A. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GAGA uptake inhibitor. Epilepsia. 36:1995;612-626.
33. Thompson M.S., Groes L., Schwietert H.R. et al. An open-label sequence listed two period crossover pharmacokinetic trial evaluating the possible interaction with erythromycin during multiple administration to healthy volunteers (abstract). Epilepsia. 38(Suppl. 3):1997;S64.
34. Wilson E.A., Brodie M.J. New antiepileptic drugs. Brodie M.J., Treiman D.M. Bailliere's Clinical Neurology: Modem Management of Epilepsy. 1996;Bailliere's Tindall, London.